IJCS | Volume 33, Nº1, January / February 2019

54 24. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes. Arch Intern Med. 2008;168(8):847-54. 25. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123(18):2006-13. 26. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, Burkman G, Siwamogsatham S, Patel A, et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol. 2016;1(5):510-8. 27. Kelly JP, Mentz RJ, MebazaaA, VoorsAA, Butler J, Roessig L, et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol. 2015;65(16):1668-82. 28. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007;50(8):768-77. 29. Martínez-Sellés M, Doughty RN, Poppe K, Whalley GA, Earle N, Tribouilloy C, et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. Eur J Heart Fail. 2012;14(5):473-9. 30. Gómez-Otero I, Ferrero-Gregori A, Varela Román A, Seijas Amigo J, Pascual-Figal DA, Delgado Jiménez J, et al. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure. Rev Esp Cardiol (Engl Ed). 2017;70(5):338-46. 31. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-85. 32. Voors AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, et al. Development and validation of multivariablemodels to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail. 2017;19(5):627-34. 33. Löfman I, Szummer K, DahlströmU, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1606-14. 34. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients withmid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail. 2017;19(10):1258-69. 35. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001-7. 36. Cleland JGF, Bunting K V, Flather MD, Altman DG, Holmes J, Coats AJS, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double- blind randomized trials. Eur Heart J. 2018;39(1):26-35. 37. Lund L. European Society of Cardiology. Candesartan provides similar benefit for patients with mid- range ejection fraction as those with reduced ejection fraction [Internet]. 2017 [citado fev. 2019]. Disponível em: https://www.escardio.org/Congresses- &-Events/Heart-Failure/ Congress-resources/News/candesartan-provides-similar-benefit-for- patients-with-mid-range-ejection-fracti. 38. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455-62. Cavalcanti et al. Decompensated heart failure with intermediate ejection fraction Int J Cardiovasc Sci. 2020;33(1):45-54 Original Article This is an open-access article distributed under the terms of the Creative Commons Attribution License